Pelthos Therapeutics has dosed the first patient in a Phase 1b/2a study of CT2000, a topical NaV1.7 inhibitor eye drop for patients with moderate to severe dry eye disease who experience chronic ocular pain. The adaptive, placebo-controlled trial begins with an ascending-dose Phase 1 segment incorporating acute ocular pain measures, followed by a 28-day Phase 2a maximum-tolerated dose period to assess safety and clinical efficacy. Topline results are targeted for the end of 2026.
The core development is Pelthos’ subsidiary, Channel Therapeutics, moving its lead ophthalmic asset into human testing through its Australian arm. CT2000 is a novel formulation of CC8464 designed to locally inhibit NaV1.7 in corneal sensory nerves. The program builds on preclinical signals reported in 2025 across models of acute and chronic ocular pain, positioning CT2000 as a potential alternative to steroids, NSAIDs, lubricants, and anesthetics that are either variably effective or constrained by safety and duration-of-use limits.
Strategically, this is a diversification play from a commercial-stage company best known for topical infectious disease products into an underserved pain niche with limited approved options and high symptom burden. The choice of NaV1.7 is notable given the mixed track record of systemic inhibitors in analgesia; by localizing exposure to the ocular surface, Channel is aiming to unlock the target’s biology where corneal nerve density and accessibility may enable meaningful effect with reduced systemic risk. Running first-in-human work in Australia offers speed, cost, and operational predictability via established early-phase ophthalmology networks and a regulatory environment conducive to adaptive designs—useful for a small-cap sponsor seeking to compress time to proof of concept.
For trial operators and sites, the design signals two operational challenges that will determine whether CT2000 produces a credible signal. First, patient selection: chronic ocular surface pain in dry eye spans nociceptive and neuropathic phenotypes with variable correlation to signs, which has confounded prior symptom-focused programs. Sites will need rigorous screening, standardized pain assessments, and tight control of background therapies. Second, endpoint quality: acute pain readouts in Phase 1 may be straightforward, but sustained symptom reduction over 28 days with concurrent ocular safety—corneal staining, epithelial integrity, IOP, visual acuity—will be scrutinized. Expect sponsors to lean on ePRO diaries and centralized data review to manage placebo effects, which are historically high in dry eye symptom studies.
CROs with ophthalmology depth stand to benefit from the program’s need for consistent esthesiometry, imaging, and safety monitoring across dispersed sites, while eClinical vendors could see demand for pain-scale validation and adherence tracking appropriate for at-home dosing. Regulators will watch the construct validity of “chronic ocular pain associated with dry eye” as a label concept; unlike dry eye signs-and-symptoms frameworks, a pure pain indication is less trodden in ophthalmology, and alignment on endpoints and responder definitions will be pivotal if Channel intends to migrate to U.S. or EU pivotal pathways.
The near-term read-through lies in whether the ascending-dose phase demonstrates a clean ocular tolerability window without anesthetic-like corneal toxicity and shows a directional pain signal that justifies the 28-day evaluation. Recruitment pace will be another indicator: identifying patients with persistent pain disproportionate to surface signs is non-trivial and could elongate timelines. Looking ahead, the key questions are the durability of effect beyond one month, the ability to segment responders by phenotype to de-risk Phase 2/3, and whether the sponsor can secure early regulatory dialogues to validate a pain-centric endpoint strategy. If CT2000 can deliver a reproducible, clinically meaningful symptom reduction with an acceptable safety profile, it could reset expectations for localized NaV1.7 inhibition—yet the field’s history with subjective endpoints and placebo response means the burden of proof will be high.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
